IN (Infinit) 24-hour volatility at 109.5%: $6 million seed round completed and surging trading volume drive dramatic fluctuations
Bitget Pulse2026/04/15 16:02Volatility Overview
In the past 24 hours, the price of IN surged from a low of $0.06694 to a high of $0.14022, currently trading at $0.07983, with a price amplitude of 109.5%. The 24-hour trading volume has expanded significantly to approximately $55.78 million (CMC data), a sharp increase from usual levels, indicating increased capital activity.
Brief Analysis of the Abnormal Movement
- Seed round financing completed: On April 15, Infinit completed a $6 million seed round led by an investor. As an AI-driven DeFi abstraction layer project, it has attracted market attention and directly triggered the price surge.
- Unusually large trading volume: 24-hour trading volume reached $55.78 million–$151 million, accompanied by an RSI of 81 (overbought). Early data showed an abnormal 134x volume, suspected to be a case of smart money accumulation and pump.
Market Perspective and Outlook
Market sentiment has turned euphoric, with community discussions focusing on the positive financing news and volume spike. Posts related to Infinit Labs (@Infinit_Labs) show a short-term rally of 16.88%, but the RSI of 81 signals an "euphoric stretch, dump incoming." Analysts recommend waiting for a pullback to $0.06041 to confirm a reversal, avoiding FOMO. If the structure holds, the market may continue to rise; otherwise, there is a risk of a correction.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.
Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched
San Francisco Fed President Daly stated that the traditional "wait and see" approach to supply-side shocks has been abandoned, noting that businesses in her district are tending to pass rising costs on to consumers and that current inflation risks are "skewed fully to the upside." Cleveland Fed President Hammack said that once the public forms an "inflationary mindset," the difficulty of monetary policy regulation will increase significantly, and the required interest rate hikes will then exceed expectations.
Australian Dollar crumbles as job losses shatter RBA rate hike hopes
Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity
Deutsche Bank believes that the recent sell-off of CoreWeave lacks sufficient company fundamentals to justify it, and the sharp price correction has instead created a buying opportunity for investors.
Crypto prices
More
